Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074282 · ClinicalTrials.gov registry record · Phase 2
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00074282 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 102 participants.
The verdict
NCT00074282, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as pentostatin, cyclophosphamide, and CAMPATH-1H work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well pentostatin, cyclophosphamide, rituximab, and CAMPATH-1H work in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
Interventions
- DRUG Alemtuzumab
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG pentostatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2005-04-14 |
| Est. Completion | 2018-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074282
The ClinicalTrials.gov registry entry for NCT00074282 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Alemtuzumab is the first listed.
NCT00074282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00074282 about?
NCT00074282 is a clinical study titled "Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL". RATIONALE: Drugs used in chemotherapy, such as pentostatin, cyclophosphamide, and CAMPATH-1H work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substanc...
What is the current status of trial NCT00074282?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2005-04-14. Estimated completion is 2018-05-06.
What interventions are being tested in trial NCT00074282?
The interventions under investigation include: Alemtuzumab (DRUG), cyclophosphamide (DRUG), rituximab (BIOLOGICAL), pentostatin (DRUG).
Who is sponsoring clinical trial NCT00074282?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.